DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Sanofi (ADR) (NYSE: SNY)



company name or ticker
Company Photos
(Click to zoom)

Could Incoming Threats Sink MannKind Corporation?

Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?

Alnylam's Cardiac Amyloidosis Drug Gets Orphan Status - Analyst Blog

Amgen And Sanofi Face Final Check Before Start Of PCSK9 Chase

Sanofi And Regeneron's Other Potential Blockbuster

Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog

MannKind, Front and Center: The Best Product Doesn’t Always Equal the Best Stock

The Motley Fool's own Michael Douglass and Todd Campbell dig into MannKind Corp.'s first quarter earnings to see if MannKind is a bargain, or a bust.

Health Care Sector Update for 05/21/2015: CALA, DRNA, REGN

MannKind's Afrezza Inhaled Insulin: A Game Changer For Seniors With Diabetes

Has MannKind Stock Finally Bottomed Out?

Sanofi's Trying To Go On Offense While Playing Defense

See More Articles...